Status:
ENROLLING_BY_INVITATION
EXPLORING EFFECTIVENESS OF LOW LEVEL LASER THERAPY IN THE TREATMENT OF PATIENTS WITH BELLS PALSY
Lead Sponsor:
University of Lahore
Conditions:
Bell Palsy
Bell's Palsy
Eligibility:
All Genders
Phase:
NA
Brief Summary
The aim of the proposed research is to explore effectiveness of Low Level LASER Therapy in the country and to compare its effectiveness with routine physiotherapy. The societal benefit of submitted re...
Detailed Description
Annually, incidence of Bell's Palsy ranges between 1 to 4 per 10,000 individuals globally. From Pakistan figures highlight that the incidence rate of Bell's palsy in Pakistan may be above the internat...
Eligibility Criteria
Inclusion
- • A confirmed diagnosis of idiopathic facial (Bell's) palsy by a certified neurologist or Physician is required (Heckmann, Urban, Pitz, Guntinas-Lichius, \& Gágyor, 2019).
- Both male and female patients, aged between 18 and 80 years (Holland \& Bernstein, 2014).
- Symptom onset within the range of 72 hours to 7 days (Petruzzelli \& Hirsch, 1991).
- A baseline House-Brackmann score of 2 to 4 is necessary (Bylund et al., 2021).
- Availability for the entire trial duration and all subsequent follow-up visits.
- Absence of any prior treatments (e.g., corticosteroids) for the current Bell's palsy episode.
Exclusion
- • Alternate diagnoses that can explain Bell's palsy (e.g., Lyme disease, Ramsay Hunt syndrome) (Crouch, Hohman, Moody, \& Andaloro, 2023).
- History of recurrent Bell's palsy episodes.
- Presence of severe medical conditions such as uncontrolled diabetes or autoimmune disorders.
- Pregnancy or lactation. Use of concurrent medications that could interfere with facial nerve function.
- Exposure to LLLT in the past 3 months.
- Active skin infections or lesions in the targeted treatment area.
- Conditions or medications that induce photosensitivity.
- Cognitive impairments that may interfere with comprehension or feedback about the trial.
- Participation in another trial in the past month.
- Traumatic, inflammatory, or infectious conditions including trauma, nerve root issues, metabolic/spinal pathologies, previous spinal surgeries, or postpartum pain due to pregnancy (Singh \& Deshmukh, 2022)
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07191808
Start Date
October 1 2025
End Date
December 1 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NACE
Faisalābad, Pakistan, 38090